Viemed Healthcare Q3 revenue rises, but slightly misses estimates
Reuters2026/11/04 22:22
Overview
US home-based healthcare provider's Q3 revenue grew 12% yr/yr, slightly missing analyst expectations
Company raised low end of full-year revenue guidance and narrowed adjusted EBITDA outlook
Outlook
Viemed expects 2026 revenue between $316 mln and $320 mln
Company narrows 2026 Adjusted EBITDA outlook to $64 mln-$66 mln
Net capital expenditures for 2026 now seen at 8.0%-9.0% of revenue
Result Drivers
VENTILATOR PATIENT VOLUME - Co said higher average patient volumes drove growth in ventilator rental revenue
PAP AND SLEEP RESUPPLY - Co reported strong growth in PAP therapy and sleep resupply patient counts
OPERATING LEVERAGE - Co attributed improved profitability to operating leverage and efficiency gains from earlier investments
Company press release: ID:nACS3NfVCa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q3 Revenue |
Slight Miss* |
$80.67 mln |
$80.78 mln (3 Analysts) |
Q3 Net Income Attributable to Shareholders |
|
$4.64 mln |
|
Q3 Gross Profit |
|
$46.19 mln |
|
Q3 Income from Operations |
|
$6.96 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Viemed Healthcare Inc is $12.50, about 32.2% above its November 3 closing price of $9.46
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 21 three months ago
Reuters Recommended Reads
Nov 3 - Addus HomeCare Q3 adjusted EPS beats estimates; to acquire AccentCare personal care division
Nov 3 - Senior care provider InnovAge's Q1 revenue beats as participants increase
Nov 3 - AdaptHealth posts Q3 loss due to goodwill impairment charge
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
